Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

218
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
218
Assessment of the Rectum and Anus01:25

Assessment of the Rectum and Anus

288
Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
288
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

232
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
232
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
158
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

227
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
227

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Paraneoplastic syndrome with intestinal pseudo-obstruction in a patient with small cell lung carcinoma: a case report and literature review.

The Journal of international medical research·2025
Same author

[Molecular mechanism of Xiangsha Liujunzi Decoction in treating chronic atrophic gastritis based on transcriptome sequencing technology].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2024
Same author

Solitary scalp folliculocystic and collagen hamartoma caused by c.2353C>T TSC2 somatic mutation in a sporadic case of tuberous sclerosis complex with calvarial fibrous dysplasia.

European journal of dermatology : EJD·2023
Same author

Clinical Application of Microscope-Assisted Minimally Invasive Anterior Lumbar Interbody Fusion.

Journal of visualized experiments : JoVE·2023
Same author

Decreased lymphocyte count before conditioning is associated with BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

International immunopharmacology·2023
Same author

Stress of cupric ion and oxytetracycline in Chlorella vulgaris cultured in swine wastewater.

The Science of the total environment·2023

相关实验视频

Updated: Jul 26, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K

与Osimertinib相关的结肠粘膜扩散拥堵

Xiao-Jun Ren1, Ming-Hong Lei2, Ying-Xia Cheng3

  • 1Department of Gastroenterology & Hepatology, Dazhou Integrated TCM and Western Medicine Hospital: Dazhou Second People's Hospital, Dazhou, Sichuan, China.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
|June 20, 2023
PubMed
概括

奥西默提尼布是治疗非小细胞肺癌 (NSCLC) 的药物,可能会导致胃肠道出血. 停止使用这种EGFR抑制剂导致症状消失,这表明患者存在潜在风险.

关键词:
在EGFR的突变中.肺癌是一种肺癌.奥西默蒂尼布 (Osimertinib) 是一种药物.案例报告案例报告

更多相关视频

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

47.0K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.0K

相关实验视频

Last Updated: Jul 26, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K
Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

47.0K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.0K

科学领域:

  • 在瘤学瘤学.
  • 胃肠病学 胃肠病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 非小细胞肺癌 (NSCLC) 是最常见的肺癌亚型.
  • 奥西默提尼布是推的一线治疗,用于EGFR突变的晚期NSCLC.
  • 胃肠道出血与其他EGFR抑制剂 (如Erlotinib和Gefitinib) 有关.

研究的目的:

  • 报告与Osimertinib治疗相关的胃肠道出血的潜在病例.
  • 突出考虑奥西默蒂尼布作为NSCLC患者胃肠道出血的潜在原因的重要性.

主要方法:

  • 一个女性NSCLC患者的病例报告,患有EGFR突变.
  • 结肠镜检查显示,在奥西默蒂尼布治疗1.5年后,结肠粘膜的扩散拥堵.
  • 治疗涉及Osimertinib的中止和粘膜保护.

主要成果:

  • 患者经历了消化道出血症状的消失,停止了Osimertinib.
  • 治疗结束后没有观察到出血的复发.
  • 在结肠镜检查期间,结肠粘膜的扩散拥堵被观察到.

结论:

  • 奥西默提尼布可能与胃肠道出血的风险增加有关.
  • 医生和患者对这种潜在风险的认识至关重要.
  • 需要进一步调查奥西默蒂尼布诱导的胃肠道毒性.